Oxaliplatin (SR96669)
Phase 3Completed 0 watching 0 views this week📈 Rising
76
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Colonic Neoplasms
Conditions
Colonic Neoplasms
Trial Timeline
Oct 1, 1998 → Apr 1, 2003
NCT ID
NCT00275210About Oxaliplatin (SR96669)
Oxaliplatin (SR96669) is a phase 3 stage product being developed by Sanofi for Colonic Neoplasms. The current trial status is completed. This product is registered under clinical trial identifier NCT00275210. Target conditions include Colonic Neoplasms.
Hype Score Breakdown
Clinical
27
Activity
18
Company
9
Novelty
9
Community
10
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00094965 | Phase 2 | Completed |
| NCT00275210 | Phase 3 | Completed |
Competing Products
6 competing products in Colonic Neoplasms
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Enzastaurin HCl | Eli Lilly | Phase 2 | 52 |
| Entereg + Entereg + placebo | Merck | Phase 2 | 52 |
| Indium labeled IMP-205xm734 | Gilead Sciences | Phase 1 | 32 |
| psyllium fibre (dietary supplement) + wheat bran (dietary supplement) + rice wheat (placebo) | Pfizer | Pre-clinical | 22 |
| Methylnaltrexone Bromide (MNTX) + Placebo | Pfizer | Approved | 84 |
| oxaliplatin | Sanofi | Approved | 84 |